
Deep Bio’s AI Predicts Breast Cancer Recurrence Risk from Standard Pathology Slides
Breakthrough study shows 87% concordance with genomic assays, opening new frontiers in precision oncology. SEOUL, NOT APPLICABLE, SOUTH KOREA, October 20, 2025 /EINPresswire.com/ -- Deep Bio Inc., a global leader in AI-driven digital pathology, …